{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:16:28Z","timestamp":1773116188433,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"9-10","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.lfs.2010.12.017","type":"journal-article","created":{"date-parts":[[2010,12,28]],"date-time":"2010-12-28T04:33:40Z","timestamp":1293510820000},"page":"418-424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001"],"prefix":"10.1016","volume":"88","author":[{"given":"Steffen","family":"Wedel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukasz","family":"Hudak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens-Michael","family":"Seibel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Juengel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Tsaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman A.","family":"Blaheta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lfs.2010.12.017_bb0005","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/(SICI)1097-0045(19990215)38:3<175::AID-PROS1>3.0.CO;2-#","article-title":"Expression of cyclin A and D proteins in prostate cancer and their relation to clinicopathological variables and patient survival","volume":"38","author":"Aaltomaa","year":"1999","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.lfs.2010.12.017_bb0010","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/med.20027","article-title":"Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies","volume":"25","author":"Blaheta","year":"2005","journal-title":"Med Res Rev"},{"issue":"20","key":"10.1016\/j.lfs.2010.12.017_bb0015","doi-asserted-by":"crossref","first-page":"10040","DOI":"10.1158\/0008-5472.CAN-06-0802","article-title":"Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells","volume":"66","author":"Cao","year":"2006","journal-title":"Cancer Res"},{"issue":"43","key":"10.1016\/j.lfs.2010.12.017_bb0020","doi-asserted-by":"crossref","first-page":"15969","DOI":"10.1073\/pnas.0604193103","article-title":"Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1","volume":"103","author":"Chen","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.lfs.2010.12.017_bb0025","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/sj.bjc.6603615","article-title":"Impact of differential cyclin D1 expression and localisation in prostate cancer","volume":"96","author":"Comstock","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lfs.2010.12.017_bb0030","doi-asserted-by":"crossref","DOI":"10.1111\/j.1464-410X.2009.08538.x","article-title":"Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics","author":"Dai","year":"2009","journal-title":"BJU Int"},{"issue":"Suppl 5","key":"10.1016\/j.lfs.2010.12.017_bb0035","first-page":"S1","article-title":"NCCN Task Force Report: mTOR inhibition in solid tumors","volume":"6","author":"Figlin","year":"2008","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.lfs.2010.12.017_bb0040","article-title":"A phase II study of RAD001 in men with hormone-refractory metastatic prostate cancer","author":"George","year":"2008"},{"issue":"1","key":"10.1016\/j.lfs.2010.12.017_bb0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/14728222.6.1.103","article-title":"Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma","volume":"6","author":"Graff","year":"2002","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"10.1016\/j.lfs.2010.12.017_bb0050","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/(SICI)1097-0045(19990101)38:1<40::AID-PROS5>3.0.CO;2-I","article-title":"Overexpression of cyclin D1 is rare in human prostate carcinoma","volume":"38","author":"Gumbiner","year":"1999","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.lfs.2010.12.017_bb0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pros.20022","article-title":"Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer","volume":"59","author":"Halkidou","year":"2004","journal-title":"Prostate"},{"issue":"8B","key":"10.1016\/j.lfs.2010.12.017_bb0060","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/j.1582-4934.2008.00436.x","article-title":"The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo","volume":"13","author":"Jones","year":"2009","journal-title":"J Cell Mol Med"},{"issue":"8","key":"10.1016\/j.lfs.2010.12.017_bb0065","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/pros.21120","article-title":"Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation","volume":"70","author":"Kobayashi","year":"2010","journal-title":"Prostate"},{"issue":"11","key":"10.1016\/j.lfs.2010.12.017_bb0070","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/pros.20410","article-title":"Expression of mTOR signaling pathway markers in prostate cancer progression","volume":"66","author":"Kremer","year":"2006","journal-title":"Prostate"},{"issue":"12","key":"10.1016\/j.lfs.2010.12.017_bb0075","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.4161\/cc.7.12.6166","article-title":"Targeting prostate cancer based on signal transduction and cell cycle pathways","volume":"7","author":"Lee","year":"2008","journal-title":"Cell Cycle"},{"issue":"34","key":"10.1016\/j.lfs.2010.12.017_bb0080","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1038\/onc.2008.104","article-title":"CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factor","volume":"27","author":"Liu","year":"2008","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.lfs.2010.12.017_bb0085","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/pros.10341","article-title":"Differential expression of cell cycle regulatory molecules and evidence for a \"cyclin switch\" during progression of prostate cancer","volume":"58","author":"Maddison","year":"2004","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.lfs.2010.12.017_bb0090","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1158\/1078-0432.CCR-09-1385","article-title":"Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels","volume":"16","author":"Mahalingam","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.lfs.2010.12.017_bb0095","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1083\/jcb.200212172","article-title":"Alpha(v)beta3 integrin expression up-regulates cdc2, which modulates cell migration","volume":"161","author":"Manes","year":"2003","journal-title":"J Cell Biol"},{"issue":"17","key":"10.1016\/j.lfs.2010.12.017_bb0100","first-page":"4291","article-title":"Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage","volume":"59","author":"McMenamin","year":"1999","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.lfs.2010.12.017_bb0105","first-page":"769","article-title":"Expression profile of class I histone deacetylases in human cancer tissues","volume":"18","author":"Nakagawa","year":"2007","journal-title":"Oncol Rep"},{"issue":"5","key":"10.1016\/j.lfs.2010.12.017_bb0110","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2353\/ajpath.2009.080751","article-title":"Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases","volume":"174","author":"Neuwirt","year":"2009","journal-title":"Am J Pathol"},{"issue":"12","key":"10.1016\/j.lfs.2010.12.017_bb0115","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.4161\/cc.7.12.6024","article-title":"Downregulation of both p21\/Cip1 and p27\/Kip1 produces a more aggressive prostate cancer phenotype","volume":"7","author":"Roy","year":"2008","journal-title":"Cell Cycle"},{"issue":"3","key":"10.1016\/j.lfs.2010.12.017_bb0120","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1464-410X.2007.07014.x","article-title":"Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men","volume":"100","author":"Shimizu","year":"2007","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.lfs.2010.12.017_bb0125","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/1535-7163.MCT-06-0328","article-title":"Inhibitory effect of snake venom toxin from Vipera lebetina turanica on hormone-refractory human prostate cancer cell growth: induction of apoptosis through inactivation of nuclear factor kappaB","volume":"6","author":"Son","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.lfs.2010.12.017_bb0130","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-07-4306","article-title":"Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors","volume":"14","author":"Verheul","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.lfs.2010.12.017_bb0135","first-page":"375","article-title":"De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc","volume":"33","author":"Wang","year":"2008","journal-title":"Int J Oncol"},{"issue":"4","key":"10.1016\/j.lfs.2010.12.017_bb0140","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/jcb.22451","article-title":"Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways","volume":"109","author":"Wang","year":"2010","journal-title":"J Cell Biochem"},{"issue":"3","key":"10.1016\/j.lfs.2010.12.017_bb0145","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.bjc.6604199","article-title":"Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy","volume":"98","author":"Weichert","year":"2008","journal-title":"Br J Cancer"},{"issue":"14","key":"10.1016\/j.lfs.2010.12.017_bb0150","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1158\/0008-5472.CAN-05-0487","article-title":"Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo","volume":"66","author":"Xia","year":"2006","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.lfs.2010.12.017_bb0155","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1158\/0008-5472.CAN-08-4385","article-title":"Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer","volume":"69","author":"Zhang","year":"2009","journal-title":"Cancer Res"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320510005588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320510005588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:09:40Z","timestamp":1758398980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320510005588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":31,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0024320510005588"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2010.12.017","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2010.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}